Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06172751 · ClinicalTrials.gov registry record
TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause
A clinical trial of Hypereosinophilic Syndrome (HES), sponsored by AstraZeneca.
- Completed
- Registry status
- 250
- Enrollment target
- 1
- Study location
NCT06172751 is a study of Hypereosinophilic Syndrome (HES) that has completed, run by AstraZeneca. The registered enrollment target is 250 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06172751, a study of Hypereosinophilic Syndrome (HES), has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to build the knowledge base on clinical characteristics, clinical management, and treatment outcomes of HES.
Conditions Studied
Interventions
- OTHER no intervention
Study Locations (1)
Massachusetts
- Research Site - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2023-12-15 |
| Est. Completion | 2024-04-26 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06172751
The ClinicalTrials.gov registry entry for NCT06172751 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypereosinophilic Syndrome (HES) appearing as the primary indexed condition, and to 1 intervention - of which no intervention is the first listed.
NCT06172751 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06172751 about?
NCT06172751 is a clinical study titled "TrinetX Study of Hypereosinophilic Syndrome (HES) Without an Identifiable Non-haematological Secondary Cause". The purpose of this study is to build the knowledge base on clinical characteristics, clinical management, and treatment outcomes of HES.
What is the current status of trial NCT06172751?
This trial is currently completed. The enrollment target is 250 participants. The study started on 2023-12-15. Estimated completion is 2024-04-26.
What conditions does trial NCT06172751 study?
This clinical trial studies the following conditions: Hypereosinophilic Syndrome (HES).
What interventions are being tested in trial NCT06172751?
The interventions under investigation include: no intervention (OTHER).
Who is sponsoring clinical trial NCT06172751?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06172751 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.